Tests edaravone with clot-busting drug treatment for acute ischemic stroke
Tests edaravone added to clot-busting treatment in adults with a sudden ischemic stroke.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07119021, who can take part
Where in China
- Beijing Tiantan Hospital of Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijun Ji
- Trial code
- NCT07119021
- Record updated
- 12 August 2025
- Original description
EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.Read full original descriptionShow less
Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)
EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.
Inclusion: Age 18-80 years; Acute ischemic stroke as defined by the International Health Organization (WHO) and confirmed by cranial CT; Onset within a 4.5-hour time window; NIHSS score of 6-24; Meet the criteria for intravenous thrombolysis in acute ischemic stroke recommended by international guidelines; Patient or family consent.
Exclusion: Comorbidity with other serious diseases that affect outcome determination; Comorbidity with other serious diseases that affect prognostic regression; Comorbidity with other serious diseases with a life expectancy of less than 1 year; Pregnant women, women in labor, and patients in the puerperium.